Coya Therapeutics Inc (COYA)

$5.86 +0.20 (3.53%)
Market Cap 137.46M
Revenue (ttm) 7.95M
Net Income (ttm) -21.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -267.04%
Debt to Equity Ratio 0.00
Volume 107,400
Avg Vol 172,026
Day's Range N/A - N/A
Shares Out 23.46M
Stochastic %K 72%
Beta 0.51
Analysts Strong Sell
Price Target $15.19

Company Profile

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated...

Industry: Biotechnology
Sector: Healthcare
Phone: 800 587 8170
Address:
5850 San Felipe St., Suite 500, Houston, United States
foreverboner
foreverboner Jul. 4 at 2:02 AM
$COYA The pumpers here need to improve their spelling and grammar. This is kind of an embarassing thread. Do better.
0 · Reply
crabbypatty31
crabbypatty31 Jul. 3 at 11:04 PM
$COYA Just added this to my watch list and initiating a small position on Monday. Love their mission🥰
1 · Reply
john_Ennis
john_Ennis Jul. 3 at 8:55 PM
$COYA my guess is tgat 15 could buy it now. 20 would be good. Any other estimates ?
1 · Reply
john_Ennis
john_Ennis Jul. 3 at 8:52 PM
$COYA Starting to be obvious that our combo 302 is making a difference. More data will raise tge price. Someone needs to take this out or they may lose it.
1 · Reply
zampy
zampy Jul. 3 at 7:34 PM
$COYA $COYA will never see $8.X as an independent company in my opinion. The segment on Good Morning America with our Dr Merit Cudkowicz she explicitly highlighted the experimental addition ( COYA'S IN MY STRING OPINION AS ON OUR CLINICAL ADVISORY BOARD) emphasizing that the specific clinical trial therapy decreases inflammation and stating..." I think that helped him a lot." MY TAKEAWAY OUR COMBINATION THERAPY IS WORKING...not a placebo as medical fact that doesnt decrease inflammation!! Conclusion: Drug appears to be doing what we believe based on what Dr Cudkowicz said with Chris.
0 · Reply
zampy
zampy Jul. 3 at 3:18 PM
$COYA A heartfelt thanks to all the dedicated shareholders here in $COYA. Your steady backing and belief in the science are what keeps this company moving forward day after day. We are all funding the mission and helping our great team of Doctor's and all $COYA personnel msking this mission possible. Bt buying shares in $COYA you are helping in the funding and letting our great team Dr Appel..Dr Grossman..Dr Arun Swaminathan get into the end zone to help our brothers and sisters. Without the shareholders this mission would not be possible. This is far more about #s this is about giving our brothers and sisters with ALS a real chance for quality of life. Every step forward we advance this collectively we should all feel good about ourselves that we MAKE A DIFFERENCE in a person's life. Thank you to everyone for bringingbus into the red zone now lets get in the end zone!! This will work...it has to!!
0 · Reply
Jwa68
Jwa68 Jul. 3 at 1:50 PM
$COYA He is on our drug... https://youtu.be/vGdqmYPwRu4?is=ENek--edDhPpujks
2 · Reply
john_Ennis
john_Ennis Jul. 3 at 1:43 PM
$COYA have a good long weekend everyone. Spend time with family and friends and come back Monday morning for rhe next chapter of Coya 302
0 · Reply
AgentMulder
AgentMulder Jul. 3 at 1:26 PM
$COYA Only #1176 watchers, definitely flying under the radar! Doc Reddy will/should make a move soon🙏🙏🙏
1 · Reply
microcapspeculator
microcapspeculator Jul. 2 at 9:35 PM
$COYA Thank you to everyone who joined us for our webinar, "Beyond the Hit: How Repetitive Head Trauma, Inflammation, and Neurodegenerative Disease Intersect." We were honored to welcome Stanley Appel, MD, @leighsteinberg, and Fred Grossman, DO, FAPA, for an engaging discussion moderated by @SolomonsWisdom. Together, they explored the growing understanding of how repetitive head trauma and chronic inflammation may contribute to #neurodegenerative diseases such as #CTE and #ALS, while emphasizing the importance of continued research, collaboration, and innovation to advance new treatment approaches. If you missed the live event, tune into the recording here: youtube.com/watch?v=YS4ckO… https://youtu.be/YS4ckOYQuys?is=FKkFVUJ8phUthVk6
0 · Reply
Latest News on COYA
Coya Therapeutics Slides: Investor presentation

Jun 29, 2026, 7:00 AM EDT - 5 days ago

Coya Therapeutics Slides: Investor presentation

Coya Therapeutics Transcript: AGM 2026

Jun 25, 2026, 1:00 PM EDT - 9 days ago

Coya Therapeutics Transcript: AGM 2026

Coya Therapeutics Transcript: Investor update

Jun 24, 2026, 4:00 PM EDT - 10 days ago

Coya Therapeutics Transcript: Investor update

Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting

Jun 18, 2026, 8:00 AM EDT - 16 days ago

Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting

Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease

Jun 15, 2026, 8:00 AM EDT - 19 days ago

Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease

Coya Therapeutics initiates first cohort of patients in ALSTARS trial

2026-06-08T12:27:28.000Z - 26 days ago

Coya Therapeutics initiates first cohort of patients in ALSTARS trial

Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase

Jun 8, 2026, 8:00 AM EDT - 26 days ago

Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase

Coya Therapeutics initiated with a Buy at Roth Capital

2026-06-05T08:20:06.000Z - 4 weeks ago

Coya Therapeutics initiated with a Buy at Roth Capital

Coya Therapeutics Slides: Investor presentation

Jun 1, 2026, 7:00 AM EDT - 4 weeks ago

Coya Therapeutics Slides: Investor presentation

Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit

May 27, 2026, 8:00 AM EDT - 5 weeks ago

Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit

Coya Therapeutics Proxy statement: Proxy filing

May 13, 2026, 8:00 AM EDT - 7 weeks ago

Coya Therapeutics Proxy statement: Proxy filing

Coya Therapeutics Proxy statement: Proxy filing

May 13, 2026, 8:00 AM EDT - 7 weeks ago

Coya Therapeutics Proxy statement: Proxy filing

Coya Therapeutics granted FDA Fast Track Designation for COYA 302

2026-05-12T11:54:30.000Z - 7 weeks ago

Coya Therapeutics granted FDA Fast Track Designation for COYA 302

Coya Therapeutics reports Q1 EPS (32c), consensus (39c)

2026-05-12T11:49:47.000Z - 7 weeks ago

Coya Therapeutics reports Q1 EPS (32c), consensus (39c)

Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

May 12, 2026, 7:35 AM EDT - 7 weeks ago

Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

May 12, 2026, 7:30 AM EDT - 7 weeks ago

Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics Earnings release: Q1 2026

May 12, 2026, 7:30 AM EDT - 7 weeks ago

Coya Therapeutics Earnings release: Q1 2026

Coya Therapeutics Quarterly report: Q1 2026

May 12, 2026, 7:30 AM EDT - 7 weeks ago

Coya Therapeutics Quarterly report: Q1 2026

Coya Therapeutics Slides: Investor presentation

May 11, 2026, 2:00 AM EDT - 7 weeks ago

Coya Therapeutics Slides: Investor presentation

Coya Therapeutics Slides: Corporate presentation

May 1, 2026, 7:00 AM EDT - 2 months ago

Coya Therapeutics Slides: Corporate presentation

Coya Therapeutics announces publication of research on COYA 302

2026-04-09T12:26:37.000Z - 3 months ago

Coya Therapeutics announces publication of research on COYA 302

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

Apr 9, 2026, 8:00 AM EDT - 3 months ago

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

Coya Therapeutics Executive Chairman Howard Berman steps down

2026-04-02T12:17:50.000Z - 3 months ago

Coya Therapeutics Executive Chairman Howard Berman steps down

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

Coya Therapeutics Slides: Investor presentation

Apr 2, 2026, 7:00 AM EDT - 3 months ago

Coya Therapeutics Slides: Investor presentation

Coya publishes study showing reduction in regulatory T cell function in FTD

2026-03-18T12:38:33.000Z - 3 months ago

Coya publishes study showing reduction in regulatory T cell function in FTD

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Mar 18, 2026, 8:00 AM EDT - 3 months ago

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

Mar 16, 2026, 8:00 AM EDT - 3 months ago

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

Coya Therapeutics Annual report: Q4 2025

Mar 16, 2026, 8:00 AM EDT - 3 months ago

Coya Therapeutics Annual report: Q4 2025

Coya Therapeutics Earnings release: Q4 2025

Mar 16, 2026, 8:00 AM EDT - 3 months ago

Coya Therapeutics Earnings release: Q4 2025

Coya Therapeutics Registration statement: Registration Filing

Mar 16, 2026, 8:00 AM EDT - 3 months ago

Coya Therapeutics Registration statement: Registration Filing

Coya Therapeutics Transcript: Status update

Feb 17, 2026, 3:00 PM EST - 4 months ago

Coya Therapeutics Transcript: Status update

Coya Therapeutics Slides: Status update

Feb 17, 2026, 3:00 PM EST - 4 months ago

Coya Therapeutics Slides: Status update

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Feb 10, 2026, 8:00 AM EST - 5 months ago

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Coya Therapeutics to sell 2.522M shares at $4.40 in private placement

2026-01-30T13:15:29.000Z - 5 months ago

Coya Therapeutics to sell 2.522M shares at $4.40 in private placement

RDY

Coya Therapeutics Announces $11.1 Million Private Placement

Jan 30, 2026, 8:00 AM EST - 5 months ago

Coya Therapeutics Announces $11.1 Million Private Placement

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Jan 20, 2026, 8:00 AM EST - 5 months ago

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

Jan 8, 2026, 8:00 AM EST - 6 months ago

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

Coya Therapeutics announces FDA acceptance of COYA 302 IND application

2026-01-05T13:05:21.000Z - 6 months ago

Coya Therapeutics announces FDA acceptance of COYA 302 IND application

Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)

Jan 5, 2026, 8:00 AM EST - 6 months ago

Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)

Coya announces Health Canada acceptance of COYA 302 clinical trial application

2025-12-23T13:11:52.000Z - 6 months ago

Coya announces Health Canada acceptance of COYA 302 clinical trial application

Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Dec 23, 2025, 8:00 AM EST - 6 months ago

Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics commences dosing in ALSTARS trial

2025-12-09T13:11:58.000Z - 7 months ago

Coya Therapeutics commences dosing in ALSTARS trial

Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS

Dec 9, 2025, 8:00 AM EST - 7 months ago

Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS

Coya Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 8:45 AM EST - 7 months ago

Coya Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Coya Therapeutics Slides: Investor Presentation

Nov 30, 2025, 6:00 PM EST - 7 months ago

Coya Therapeutics Slides: Investor Presentation

Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences

Nov 25, 2025, 8:00 AM EST - 7 months ago

Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences

Coya Therapeutics reports Q3 EPS (13c), consensus (30c)

2025-11-12T13:20:43.000Z - 8 months ago

Coya Therapeutics reports Q3 EPS (13c), consensus (30c)

Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Nov 12, 2025, 8:00 AM EST - 8 months ago

Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 8 months ago

Coya Therapeutics Quarterly report: Q3 2025

Coya Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 8:00 AM EST - 8 months ago

Coya Therapeutics Earnings release: Q3 2025

Coya Therapeutics price target raised to $17 from $16 at Lake Street

2025-11-05T13:50:45.000Z - 8 months ago

Coya Therapeutics price target raised to $17 from $16 at Lake Street

Coya Therapeutics announces results from COYA 303 in vivo animal study

2025-11-04T14:06:05.000Z - 8 months ago

Coya Therapeutics announces results from COYA 303 in vivo animal study

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

Nov 4, 2025, 8:00 AM EST - 8 months ago

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Oct 27, 2025, 4:01 PM EDT - 8 months ago

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Coya Therapeutics 3.64M Spot Secondary priced at $5.50

2025-10-24T10:35:20.000Z - 9 months ago

Coya Therapeutics 3.64M Spot Secondary priced at $5.50

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

Oct 24, 2025, 6:30 AM EDT - 9 months ago

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

Coya Therapeutics announces common stock offering, no amount given

2025-10-23T20:35:37.000Z - 9 months ago

Coya Therapeutics announces common stock offering, no amount given

Coya Therapeutics Announces Proposed Public Offering of Common Stock

Oct 23, 2025, 4:31 PM EDT - 9 months ago

Coya Therapeutics Announces Proposed Public Offering of Common Stock

Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function

Oct 7, 2025, 8:00 AM EDT - 9 months ago

Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function

Coya Therapeutics completes enrollment in IL-2 and CTLA4-Ig study

2025-09-29T12:10:10.000Z - 9 months ago

Coya Therapeutics completes enrollment in IL-2 and CTLA4-Ig study

Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia

Sep 29, 2025, 8:00 AM EDT - 9 months ago

Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia

Coya Therapeutics launches ALSTARS Trial to study efficacy of COYA 302

2025-09-22T12:15:58.000Z - 10 months ago

Coya Therapeutics launches ALSTARS Trial to study efficacy of COYA 302

Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis

Sep 22, 2025, 8:00 AM EDT - 10 months ago

Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis

Coya Therapeutics’ COYA 303 shows anti-inflammatory effect in animal study

2025-09-16T12:05:25.000Z - 10 months ago

Coya Therapeutics’ COYA 303 shows anti-inflammatory effect in animal study

Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model

Sep 16, 2025, 8:00 AM EDT - 10 months ago

Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model

Coya Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025, 10:00 AM EDT - 10 months ago

Coya Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial

Sep 4, 2025, 8:00 AM EDT - 10 months ago

Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial

PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies

Sep 3, 2025, 11:50 AM EDT - 10 months ago

PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies

Coya Therapeutics to Participate at Upcoming September Investor Conferences

Sep 3, 2025, 8:34 AM EDT - 10 months ago

Coya Therapeutics to Participate at Upcoming September Investor Conferences

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Aug 25, 2025, 8:00 AM EDT - 11 months ago

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Coya Therapeutics Earnings release: Q2 2025

Coya Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Coya Therapeutics Quarterly report: Q2 2025

Coya Therapeutics Registration statement: Registration Filing

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Coya Therapeutics Registration statement: Registration Filing

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease

Jul 24, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease

Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025

Jul 22, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025

Coya Therapeutics Transcript: IAccess Alpha Virtual Best Ideas Summer Investment Conference 2025

Jun 24, 2025, 10:30 AM EDT - 1 year ago

Coya Therapeutics Transcript: IAccess Alpha Virtual Best Ideas Summer Investment Conference 2025

Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025

Jun 18, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025

Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations

Coya Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 12:30 PM EDT - 1 year ago

Coya Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 16, 2025, 10:53 AM EDT - 1 year ago

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Coya Therapeutics Proxy statement: Proxy Filing

May 16, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Proxy statement: Proxy Filing

Coya Therapeutics Proxy statement: Proxy Filing

May 16, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Proxy statement: Proxy Filing

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

May 13, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Quarterly report: Q1 2025

Coya Therapeutics Earnings release: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Earnings release: Q1 2025

Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

May 8, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

May 8, 2025, 5:00 AM EDT - 1 year ago

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

REPL

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Apr 24, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Coya Therapeutics Transcript: Planet MicroCap Showcase: VEGAS 2025

Apr 23, 2025, 2:00 PM EDT - 1 year ago

Coya Therapeutics Transcript: Planet MicroCap Showcase: VEGAS 2025

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

Apr 21, 2025, 9:51 AM EDT - 1 year ago

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

Apr 1, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Mar 26, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

Mar 18, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

Coya Therapeutics Annual report: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Annual report: Q4 2024

Coya Therapeutics Earnings release: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Earnings release: Q4 2024

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations

Feb 25, 2025, 8:15 AM EST - 1 year ago

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations

Coya Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 10:00 AM EST - 1 year ago

Coya Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Feb 6, 2025, 8:00 AM EST - 1 year ago

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:15 AM EST - 1 year ago

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Jan 21, 2025, 8:15 AM EST - 1 year ago

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

Dec 18, 2024, 8:15 AM EST - 1 year ago

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

foreverboner
foreverboner Jul. 4 at 2:02 AM
$COYA The pumpers here need to improve their spelling and grammar. This is kind of an embarassing thread. Do better.
0 · Reply
crabbypatty31
crabbypatty31 Jul. 3 at 11:04 PM
$COYA Just added this to my watch list and initiating a small position on Monday. Love their mission🥰
1 · Reply
john_Ennis
john_Ennis Jul. 3 at 8:55 PM
$COYA my guess is tgat 15 could buy it now. 20 would be good. Any other estimates ?
1 · Reply
john_Ennis
john_Ennis Jul. 3 at 8:52 PM
$COYA Starting to be obvious that our combo 302 is making a difference. More data will raise tge price. Someone needs to take this out or they may lose it.
1 · Reply
zampy
zampy Jul. 3 at 7:34 PM
$COYA $COYA will never see $8.X as an independent company in my opinion. The segment on Good Morning America with our Dr Merit Cudkowicz she explicitly highlighted the experimental addition ( COYA'S IN MY STRING OPINION AS ON OUR CLINICAL ADVISORY BOARD) emphasizing that the specific clinical trial therapy decreases inflammation and stating..." I think that helped him a lot." MY TAKEAWAY OUR COMBINATION THERAPY IS WORKING...not a placebo as medical fact that doesnt decrease inflammation!! Conclusion: Drug appears to be doing what we believe based on what Dr Cudkowicz said with Chris.
0 · Reply
zampy
zampy Jul. 3 at 3:18 PM
$COYA A heartfelt thanks to all the dedicated shareholders here in $COYA. Your steady backing and belief in the science are what keeps this company moving forward day after day. We are all funding the mission and helping our great team of Doctor's and all $COYA personnel msking this mission possible. Bt buying shares in $COYA you are helping in the funding and letting our great team Dr Appel..Dr Grossman..Dr Arun Swaminathan get into the end zone to help our brothers and sisters. Without the shareholders this mission would not be possible. This is far more about #s this is about giving our brothers and sisters with ALS a real chance for quality of life. Every step forward we advance this collectively we should all feel good about ourselves that we MAKE A DIFFERENCE in a person's life. Thank you to everyone for bringingbus into the red zone now lets get in the end zone!! This will work...it has to!!
0 · Reply
Jwa68
Jwa68 Jul. 3 at 1:50 PM
$COYA He is on our drug... https://youtu.be/vGdqmYPwRu4?is=ENek--edDhPpujks
2 · Reply
john_Ennis
john_Ennis Jul. 3 at 1:43 PM
$COYA have a good long weekend everyone. Spend time with family and friends and come back Monday morning for rhe next chapter of Coya 302
0 · Reply
AgentMulder
AgentMulder Jul. 3 at 1:26 PM
$COYA Only #1176 watchers, definitely flying under the radar! Doc Reddy will/should make a move soon🙏🙏🙏
1 · Reply
microcapspeculator
microcapspeculator Jul. 2 at 9:35 PM
$COYA Thank you to everyone who joined us for our webinar, "Beyond the Hit: How Repetitive Head Trauma, Inflammation, and Neurodegenerative Disease Intersect." We were honored to welcome Stanley Appel, MD, @leighsteinberg, and Fred Grossman, DO, FAPA, for an engaging discussion moderated by @SolomonsWisdom. Together, they explored the growing understanding of how repetitive head trauma and chronic inflammation may contribute to #neurodegenerative diseases such as #CTE and #ALS, while emphasizing the importance of continued research, collaboration, and innovation to advance new treatment approaches. If you missed the live event, tune into the recording here: youtube.com/watch?v=YS4ckO… https://youtu.be/YS4ckOYQuys?is=FKkFVUJ8phUthVk6
0 · Reply
Jwa68
Jwa68 Jul. 2 at 8:36 PM
$COYA Nice tape, quite telling relative strength. Stay the course.
0 · Reply
zampy
zampy Jul. 2 at 8:06 PM
$COYA Held 5.57 like a champ to the penny bullish trend in tack..cooled off ti RSI 57 from 71.... Outstanding
0 · Reply
Robby83
Robby83 Jul. 2 at 7:11 PM
$SLS Wish I would've held more long, need another multi-bagger. $COYA, $SLDB, and $GANX all in time.
2 · Reply
Jwa68
Jwa68 Jul. 2 at 6:59 PM
$COYA Those who know...know.
0 · Reply
Jwa68
Jwa68 Jul. 2 at 11:10 AM
$COYA The more you know...
0 · Reply
zampy
zampy Jul. 2 at 1:45 AM
$COYA 1 out of 400 at risk getting ALS general population... 1 out of 200 are at risk in the military getting ALS.. 1 out of 100 are at risk getting ALS in the NFL... Per Dr Fred G r ossman on the latest segment #BLEAV
0 · Reply
Jwa68
Jwa68 Jul. 2 at 1:33 AM
$COYA https://bleav.com/shows/bleav-in-bengals/episodes/dr-fred-grossman-on-als-research-and-chris-johnsons-diagnosis/
0 · Reply
john_Ennis
john_Ennis Jul. 1 at 8:03 PM
$COYA Maybe the last chance to buy at these prices. Any more athletes or just ordinary guys who are doing well on 302 will get out in the open soon. 2 horse race ? Get your bids in.
0 · Reply
Jwa68
Jwa68 Jul. 1 at 7:44 PM
$COYA Good spot to add or initiate, if you missed it previously. Looking for a deal by Sept month end.
1 · Reply
zampy
zampy Jul. 1 at 5:22 PM
$COYA 5.85 to 5.72 9000 shares...drag em done ezzz in nothing..Im buying cooling off
0 · Reply
zampy
zampy Jul. 1 at 3:54 PM
$COYA 15k I love this action...We have made a huge move off the bottom over 59% and EVERYONE BOTH RETAIL/ INSTITUTIONS behaving in the sandbox....
0 · Reply
zampy
zampy Jul. 1 at 3:28 PM
$COYA 15k NO RETAIL SELLING NOR INSTITUTIONS... I got filled iceberg 45 mins $5.83....great sign...Green day tmrw RSI needed red days...was 74
0 · Reply